Bone Morphogenetic Proteins (BMPs)

BMP-2 (Recombinant Human BMP-2, rhBMP-2)

Commercial name: InFuse Bone Graft (Medtronic)

Structure:

• Homodimer of two identical 114 amino acid chains
• Molecular weight: 26 kDa
• Requires dimerization for receptor binding

FDA-approved indications:

• Anterior lumbar interbody fusion (ALIF) single-level L4-S1
• Open tibial shaft fractures (acute fracture, not nonunion initially)
• Oral maxillofacial reconstruction (sinus augmentation, ridge preservation)

Off-label uses (controversial):

• Posterior lumbar fusion
• Cervical fusion (BLACK BOX WARNING - airway swelling risk)
• Long bone nonunion
• Revision arthroplasty with bone loss

Clinical dosing:

• ALIF: 12 mg total (1.5 mg/mL on absorbable collagen sponge)
• Posterolateral fusion: 12-24 mg per level (off-label)
• Nonunion: 6-12 mg depending on defect size

Doses are 100-1000 times higher than physiologic levels during normal fracture healing, contributing to adverse effects.

BMP-7 (Recombinant Human BMP-7, rhBMP-7, OP-1)

Commercial name: OP-1 Putty (Stryker) - discontinued in many markets

Structure:

• Homodimer of two 139 amino acid chains
• Molecular weight: 35 kDa
• Also known as Osteogenic Protein-1 (OP-1)

FDA status:

• Humanitarian Device Exemption (HDE) - not full FDA approval
• Limited to recalcitrant long bone nonunions where autograft failed or infeasible
• Required institutional review board approval for use

Indications (HDE):

• Recalcitrant long bone nonunions (no healing after 9+ months)
• Revision posterolateral lumbar fusion (single-level)

Comparison to BMP-2:

• Less osteogenic potency (requires higher doses)
• Potentially lower inflammatory complication rate
• More expensive and less available
• Putty formulation (vs sponge for BMP-2)

BMP-7 has been largely replaced by BMP-2 in clinical practice due to availability and regulatory issues.

Experimental and Developmental BMPs

BMP-4:

• Similar structure and function to BMP-2
• Potent osteoinductor in animal models
• No clinical development (BMP-2 dominates market)

BMP-6:

• Strong osteogenic capacity in preclinical studies
• May have advantages in large bone defects
• Phase I/II trials ongoing

BMP-9:

• Most potent osteogenic BMP in vitro
• Experimental studies in critical-size defects
• No clinical trials yet

GDF-5 (Growth Differentiation Factor-5):

• BMP family member with tendon/ligament affinity
• Experimental use in rotator cuff repair
• Clinical trials for ACL reconstruction augmentation

Most experimental BMPs have not advanced beyond preclinical studies due to the dominance of BMP-2.

Canonical BMP-Smad Signaling

The primary BMP signaling mechanism involves Smad proteins (mothers against decapentaplegic homologs).

The Smad pathway is the canonical and most important BMP signaling route for osteogenesis.

Alternative BMP Signaling Pathways

BMPs also activate Smad-independent pathways that modulate cellular responses.

Clinical significance: Non-Smad pathways contribute to the pleiotropic effects of BMPs beyond simple osteoinduction. Inflammatory responses, angiogenesis, and ectopic bone formation may involve non-Smad signaling.

Understanding both Smad and non-Smad pathways explains the complexity of BMP biology and potential off-target effects.

BMP Signaling Inhibitors

Multiple endogenous antagonists regulate BMP activity through extracellular binding or intracellular inhibition.

Extracellular Antagonists (bind BMP ligand):

• Noggin: Secreted protein, high-affinity BMP binding, prevents receptor interaction
• Chordin: Binds BMP-2/4/7, dorsalizing factor in embryogenesis
• Gremlin: BMP-2/4 antagonist, regulates limb development
• Follistatin: Primarily activin inhibitor, also binds some BMPs

Intracellular Antagonists:

• Smad6/7 (Inhibitory Smads): Compete with Smad1/5/8 for type I receptor binding, prevent phosphorylation, induce receptor degradation
• Smurf1/2 (E3 ubiquitin ligases): Target Smads and BMP receptors for proteasomal degradation

BMP antagonists provide negative feedback regulation and spatial control of bone formation during development and healing.

BMP Molecular Structure

Receptor Architecture

Tissue distribution of BMPs:

• Abundant in bone matrix (stored, released during resorption)
• Expressed during fracture healing (peak at 3 weeks)
• Present in cartilage, tendon, periosteum
• Low levels in most adult soft tissues
• High expression in embryonic development

BMP Classification by Function

Classification by Receptor Specificity

Classification by Osteogenic Potency

BMP in Spinal Fusion

FDA-approved indication: Anterior lumbar interbody fusion (ALIF), single-level L4-S1

Evidence for ALIF:

• Fusion rates: BMP-2 (95%) vs autograft iliac crest (85%) at 2 years
• Eliminates donor site morbidity (10-20% chronic pain with iliac crest harvest)
• Shorter operative time
• Equivalent clinical outcomes (ODI, VAS)

Off-label use in posterolateral fusion (controversial):

• Not FDA-approved for posterior approach
• Higher doses used (12-24 mg per level)
• Complications: ectopic bone (nerve root compression), osteolysis (screw loosening), radiculitis
• Mixed evidence on fusion rates vs autograft

Cervical spine (BLACK BOX WARNING):

• NOT approved for anterior cervical fusion
• Life-threatening complications: airway edema, hematoma, dysphagia, dysphonia
• Enclosed anterior cervical space amplifies inflammatory swelling
• Case reports of intubation, tracheostomy, death

BMP-2 in ALIF is well-established, but off-label use requires careful risk-benefit consideration.

BMP in Long Bone Nonunion

FDA-approved indication: Open tibial shaft fractures (acute, not nonunion)

Off-label use in established nonunion:

• Atrophic nonunions (lacking biological healing potential)
• Critical-size defects after debridement (infection, tumor)
• Revision surgery after failed bone grafting

Evidence:

• Govender (BESTT) trial (2002): 450 open tibial fractures; the 1.5 mg/mL rhBMP-2 group had a 44% reduction in the risk of secondary intervention for delayed/nonunion (RR 0.56, 95% CI 0.40-0.78), faster fracture and wound healing, and significantly fewer infections in Gustilo-Anderson type-III injuries
• Nonunion studies: 75-85% union rate with BMP-2 in recalcitrant tibial nonunions
• Comparable to autograft but avoids donor site morbidity

BMP-7 (OP-1) in nonunion:

• Humanitarian device exemption for recalcitrant long bone nonunions
• Required failed prior treatment (autograft or other)
• Limited availability, largely replaced by BMP-2

BMP can enhance union in challenging nonunions but must be combined with sound surgical technique.

Experimental and Off-Label BMP Uses

Revision arthroplasty with bone loss:

• Acetabular defects in revision THA
• Tibial defects in revision TKA
• Limited evidence, case series only
• Concerns about osteolysis and heterotopic ossification

Osteotomy healing enhancement:

• Periacetabular osteotomy (PAO)
• High tibial osteotomy (HTO)
• Theoretical benefit, no RCT evidence

Bone tumor reconstruction:

• Allograft-BMP composite for segmental defects
• Distraction osteogenesis acceleration
• Very limited clinical data

Oral maxillofacial:

• Sinus floor augmentation (FDA-approved)
• Ridge preservation pre-implant
• Mandibular reconstruction

Most non-approved BMP uses lack high-quality evidence and carry increased risk.

Assessing BMP Response and Bone Healing

Laboratory Assessment of BMP Biology

Research investigations (not routine clinical):

Histologic investigations (research settings):

• Bone biopsy with immunohistochemistry for Runx2, osterix
• Assessment of osteoblast differentiation markers
• Quantification of new bone formation
• Evaluation of carrier degradation

Pre-operative workup before BMP use:

• Routine pre-operative bloods (FBC, UEC, coagulation)
• Nutritional assessment (vitamin D, calcium if bone healing concern)
• Inflammatory markers if infection concern (CRP, ESR, WCC)
• No specific BMP-related tests required

Clinical Decision Making for BMP Use

BMP Dosing and Carrier Selection

Carrier Systems

BMP Application Techniques

Site-Specific Application Techniques

Combination Strategies

Post-BMP Monitoring Protocol

Managing BMP-Related Complications

Return to Activity Guidelines

BMP Clinical Outcomes Summary

Cost-Effectiveness Analysis

Long-term Outcomes

Controversies and Evidence Gaps

Global Epidemiology and Regulatory Landscape

rhBMP-2 use peaked in the United States in the late 2000s (used in roughly a quarter to a half of lumbar fusions at its height) and has since declined substantially following the 2011 Spine Journal critique (Carragee) and the 2013 independent YODA/Annals re-analysis (Fu). Uptake has always been far lower in Europe, the UK, Australia and Asia, driven by cost and a more conservative stance toward off-label use. The vast majority of BMP exposure worldwide is now in anterior or posterolateral lumbar fusion and selected long-bone trauma/nonunion.

Cost-Effectiveness Across Health Systems

Side-by-Side Guideline and Society Guidance

Registry and Large-Database Evidence

Training and Competency